MaaT Pharma (France) has raised €10M in a series A round, which will allow it to start clinical development of its autologous therapy for imbalance of the Gut Microbiome.
MaaT Pharma is developing microbiome-based therapies with an autologous (self-sourced) approach. This means that the patient suffering from dysbiosis is treated with their own microbiome, samples of which were stored when the patient was healthy.
Dysbiosis is an imbalance in the normal microbiota living in the human gut that can lead to difficult opportunitistic infections.
Since its creation in late 2014, MaaT Pharma has attracted significant attention. This Lyon-based startup had already received €2M from the world-first €160M Microbiome Fund, and developed its pre-clinical proof of concept in collaboration with the French National Institute of Agricultural Research (INRA).